Shanghai Pharmaceuticals Holding Co Ltd

Shanghai Pharmaceuticals announced that its subsidiary, Shanghai First Biochemical Pharmaceutical, has received a Drug Registration Certificate from the National Medical Products Administration for Clevidipine Injectable Emulsion, granting approval for production. The product is available in 50 ml: 25 mg and 100 ml: 50 mg specifications, registered as a Category 3 chemical drug, with the company having invested approximately 52.2 million yuan in research and development. The product is indicated for hypertensive patients who cannot take oral medication. In 2025, hospital procurement of injectable calcium channel blockers with the same mechanism in mainland China reached 911.39 million yuan. Following approval, the product is expected to benefit from medical insurance payment support, increase market share, and enhance the company's competitiveness.

Shanghai Pharmaceuticals announced that its subsidiary Changzhou Pharmaceutical Factory has received a drug registration certificate for Ruxolitinib Phosphate Tablets from the National Medical Products Administration, with specifications of 5 mg, 15 mg, and 20 mg, classified as a Category 4 chemical drug. The drug is used to treat adult patients with intermediate or high-risk primary myelofibrosis and other myelofibrosis conditions, as well as graft-versus-host disease in patients aged 12 and older. It was jointly developed by Incyte and Novartis and launched in the United States in 2011. Changzhou Pharmaceutical Factory submitted its registration and marketing application in December 2024, with cumulative research and development investment of approximately 24.81 million yuan.

Shanghai Pharmaceuticals' subsidiary SPH Sine has received a drug registration certificate from the National Medical Products Administration for Omeprazole and Sodium Bicarbonate for Oral Suspension (I), granting approval for production. The drug is primarily used for the short-term treatment of active duodenal ulcers and gastroesophageal reflux disease. Shanghai Pharmaceuticals stated that the approval will help expand its market share, but sales remain uncertain due to policy and market conditions, and reminded investors to be aware of the risks.

Shanghai Pharma announced that three products from its subsidiary Shangyao Zhonghua — Longhu Cooling Oil Classic, Longhu Cooling Oil Extra Strength, and Longhu Roll-on Essential Oil — received product licences from Health Canada on 30 July 2026. The licences are for the temporary relief of muscle and joint aches or discomfort. The company submitted the registration applications in May 2026, with cumulative registration expenses of approximately 49,500 yuan. Shanghai Pharma stated that this approval is positive for expanding overseas markets, but export business is subject to uncertainties from factors such as overseas regulations, market conditions, and exchange rate fluctuations.